Carotid artery stenosis

InspireMD Announces Warrants Exchange Listing Transfer to Nasdaq

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Angiology, Vascular diseases, Cardiovascular system, Neurosurgery, Vascular surgery, Carotid artery stenosis, Carotid stenting, Stroke, Carotid artery, NASDAQ

TEL AVIV, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Companys warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market (Nasdaq).

Key Points: 
  • TEL AVIV, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Companys warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market (Nasdaq).
  • Trading is expected to begin onJune 8, 2021, under the symbols NSPRW and NSPRZ on the Nasdaq.
  • InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.

InspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021

Retrieved on: 
Friday, May 14, 2021
Medical specialties, Neurosurgery, Vascular surgery, Finance, Carotid artery stenosis, Carotid stenting, Clinical medicine, Stroke, Ticker symbol, New York Stock Exchange, Carotid artery

b'TEL AVIV, Israel, May 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Investor Summit Conference on May 17, 2021.\nChief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:00am ET on May 17, 2021.\nInvestors can also request a one-on-one meeting with Mr. Slosman to be arranged following the conclusion of the conference.\nInspireMD seeks to utilize its proprietary MicroNet\xc2\xae technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.\nInspireMD\xe2\x80\x99s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.\n'

Key Points: 
  • b'TEL AVIV, Israel, May 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Investor Summit Conference on May 17, 2021.\nChief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:00am ET on May 17, 2021.\nInvestors can also request a one-on-one meeting with Mr. Slosman to be arranged following the conclusion of the conference.\nInspireMD seeks to utilize its proprietary MicroNet\xc2\xae technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.\nInspireMD\xe2\x80\x99s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.\n'

InspireMD Announces Stock Exchange Listing Transfer to Nasdaq

Retrieved on: 
Monday, May 10, 2021
Carotid artery stenosis, Carotid artery, Stroke

b'TEL AVIV, Israel, May 10, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Company\xe2\x80\x99s shares have been approved for listing on The Nasdaq Capital Market (\xe2\x80\x9cNasdaq\xe2\x80\x9d).

Key Points: 
  • b'TEL AVIV, Israel, May 10, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Company\xe2\x80\x99s shares have been approved for listing on The Nasdaq Capital Market (\xe2\x80\x9cNasdaq\xe2\x80\x9d).
  • InspireMD is a stronger company today than ever before, and I am proud of the extraordinary efforts of our expanding team in creating an exciting future for our company.
  • Investors and security holders are urged to read these documents free of charge on the SEC\xe2\x80\x99s web site at http://www.sec.gov.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.\n'

InspireMD to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 14, 2021

Retrieved on: 
Thursday, May 6, 2021
Medical specialties, Neurosurgery, Vascular surgery, Carotid artery stenosis, Carotid stenting, Clinical medicine, Medicine, Stroke, Carotid artery

b'TEL AVIV, Israel, May 06, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.\nChief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:10am ET on May 14, 2021.\nInvestors can also request a one-on-one meeting with Mr. Slosman to be arranged following the conclusion of the conference.\nInvestors can register for the conference here:\nInspireMD seeks to utilize its proprietary MicroNet\xc2\xae technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.\nInspireMD\xe2\x80\x99s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.\n'

Key Points: 
  • b'TEL AVIV, Israel, May 06, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.\nChief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:10am ET on May 14, 2021.\nInvestors can also request a one-on-one meeting with Mr. Slosman to be arranged following the conclusion of the conference.\nInvestors can register for the conference here:\nInspireMD seeks to utilize its proprietary MicroNet\xc2\xae technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.\nInspireMD\xe2\x80\x99s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.\n'

Silk Road Medical to Present at BofA Securities 2021 Virtual Health Care Conference

TCAR, Vascular diseases, Vascular surgery, Carotid artery stenosis, Stroke, Revascularization, Silkroad, Medicine

b'SUNNYVALE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in a fireside chat at the upcoming BofA Securities 2021 Virtual Health Care Conference.\nSilk Road Medical\xe2\x80\x99s management is scheduled to present on Wednesday, May 12, 2021 at 11:00 a.m. Eastern Time.

Key Points: 
  • b'SUNNYVALE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in a fireside chat at the upcoming BofA Securities 2021 Virtual Health Care Conference.\nSilk Road Medical\xe2\x80\x99s management is scheduled to present on Wednesday, May 12, 2021 at 11:00 a.m. Eastern Time.
  • Interested parties may access a live and archived webcast of the presentation on the \xe2\x80\x9cInvestors\xe2\x80\x9d section of the company\xe2\x80\x99s website at: https://investors.silkroadmed.com/ .\nSilk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact.
  • The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR).
  • For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter , LinkedIn and Facebook .\n'

$4.16 Billion Neurovascular Intervention Devices Market - Global Forecast to 2027 - Acquisitions and Partnerships as a Part of the Growth Strategy

Retrieved on: 
Wednesday, March 10, 2021
Medical specialties, Vascular diseases, Cerebrovascular diseases, Gross pathology, Branches of biology, Organ systems, Neurosurgery, Stroke, Carotid artery stenosis, Intracranial aneurysm, Arteriovenous malformation, Aneurysm

DUBLIN, March 10, 2021 /PRNewswire/ -- The "Neurovascular Intervention Devices Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 10, 2021 /PRNewswire/ -- The "Neurovascular Intervention Devices Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Neurovascular Intervention Devices global market is expected to grow at a high single digit CAGR to reach $4,167.4 million by 2027.
  • As a result of rapid advances, there is the great expansion in the potential therapeutic application for neurovascular diseases.
  • Neurovascular Interventional devices are used to treat intracranial aneurysm, ischemic stroke, arteriovenous malformation, carotid stenosis and other diseases like intracranial stenosis, dural fistula.

InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States

Retrieved on: 
Wednesday, February 24, 2021
Medical specialties, Angiology, Cardiovascular system, Neurosurgery, Vascular surgery, Vascular diseases, Carotid stenting, Carotid artery stenosis, Stroke, Carotid artery, Carotid endarterectomy

TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct the clinical trial for its CGuard Carotid Stent System in the United States.

Key Points: 
  • TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct the clinical trial for its CGuard Carotid Stent System in the United States.
  • HCC is ideally suited to manage this trial having supported clinical trial operations for a variety of products and indications, including with multiple carotid intervention procedures, stated Marvin Slosman, InspireMDs CEO.
  • This will be the first U.S.-based study of CGuard and our opportunity to demonstrate its potential for the prevention of stroke caused by carotid artery disease in patients in the United States.
  • We look forward to working with InspireMD on this pivotal trial of the CGuard System to help establish a new standard of care for the management of carotid artery disease and stroke prevention.

Global Vascular Screening Devices Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 27, 2021
Medical devices, Health, Cardiovascular system, Circulatory system, Vascular diseases, Medical specialties, Aneurysm, Vascular disease, Cardiovascular disease, Coronary artery disease, Artery disease, Carotid artery stenosis, Vascular surgery

For several cardiovascular diseases, vascular screening tests become very important for further analysis and treatment.

Key Points: 
  • For several cardiovascular diseases, vascular screening tests become very important for further analysis and treatment.
  • Hence, early diagnosis and treatment are of utmost importance, which is expected to impact positively on the vascular screening test market.
  • North America expected to hold a major market share in the global vascular screening devices market, due to increased vascular diseases, such as coronary artery disease, renal artery diseases, and carotid artery aneurysm, among others.
  • Hence, the aforementioned factors are expected to boost up the demand for vascular screening devices in North America.

CES 2021 Mission for the human race, Pulxion's early detection technology is here to save lives

Retrieved on: 
Thursday, January 14, 2021
Angiology, Medical specialties, Cardiovascular system, Vascular diseases, Carotid artery stenosis, Neurosurgery, Vascular surgery, Stenosis, Common carotid artery, Stroke, Carotid ultrasonography, Carotid stenting

Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the team's research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

CES 2021 Mission for the Human Race, Pulxion’s Early Detection Technology Is Here to Save Lives.

Retrieved on: 
Thursday, January 14, 2021
Health, Technology, Hospitals, Other Health, Telecommunications, Mobile, Wireless, Software, Medical specialties, Angiology, Cardiovascular system, Vascular diseases, Carotid artery stenosis, Stroke, Neurosurgery, Vascular surgery, Stenosis, Common carotid artery, Carotid ultrasonography, Carotid stenting

Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the teams research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.